our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
MTA2 expression
i
Other names: MTA2, Metastasis Associated 1 Family Member 2, Metastasis Associated Gene Family, Member 2, P53 Target Protein In Deacetylase Complex, Metastasis-Associated Protein MTA2, Metastasis-Associated 1-Like 1, MTA1-L1 Protein, MTA1L1, PID, Metastasis -Associated Gene 1-Like 1, Metastasis-Associated Protein 2, MTA1-L1
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Overall, our study suggests that MTA2 knockdown suppresses osteosarcoma cell metastasis by decreasing uPA expression via ERK signaling. This finding provides new insight into potential treatment strategies against osteosarcoma metastasis by targeting MTA2.
Taken together, these findings uncover that circMTA2 suppresses MTA2 degradation by interacting with UCHL3, thereby promoting GC progression. In conclusion, we identified a cancer-promoting axis (circMTA2/UCHL3/MTA2) in GC progression, which paves the way for us to design and synthesize targeted inhibitors as well as combination therapies.
Furthermore, deactivation of FAK using siFAK or FAK inhibitor (PF-573228, PF) synergistically contributed to PTK7 knockdown-inhibited FAK activity, MMP7 expression, and the migration and invasion abilities of HCC cells. Collectively, our findings show that PTK7 mediates HCC progression by regulating the MTA2-FAK-MMP7 axis and may be a diagnostic value for HCC patients.
2 years ago
Journal
|
PTK7 (Protein Tyrosine Kinase 7) • MTA2 (Metastasis Associated 1 Family Member 2) • MMP7 (Matrix metallopeptidase 7)
The rank correlation coefficient of MTA2 and CPNE1 protein expression in cervical squamous cell carcinoma was 0.668 (P<0.01), and the 2 expressions were positively correlated. MTA2 and CPNE1 are closely related to the occurrence and development of cervical squamous cell carcinoma and may play a synergistic role in the evolution of cervical squamous cell carcinoma.
over 2 years ago
Journal
|
MTA2 (Metastasis Associated 1 Family Member 2) • CPNE1 (Copine 1)
Our study demonstrated that MTA2 plays crucial roles in tumor progression and tumor immunity, and it could be used as a prognostic marker for various malignancies. MK-886 might be a powerful drug for HCC.
over 2 years ago
Preclinical • Journal • Tumor mutational burden • Pan tumor
|
TMB (Tumor Mutational Burden) • CD4 (CD4 Molecule) • MTA2 (Metastasis Associated 1 Family Member 2)
Furthermore, we identified MTA2 binding to the promoter of minichromosome maintenance deficient 5 (MCM5), thereby promoting GC progression. Overall, these findings strongly support the prognostic potential of the 14-TFs signature and suggest that targeting MTA2 may be a promising strategy to treat GC.
3 years ago
Journal
|
MTA2 (Metastasis Associated 1 Family Member 2) • MCM5 (Minichromosome Maintenance Complex Component 5)
Material and Methods MCF7 breast cancer cells were transfected with MTA2 overexpression vector and then treated with Doxorubicin or Paclitaxel to determine their cytotoxicity. Conclusion The epigenetic regulation of NFKB1 using MTA2 mimics has shown to increase the sensitivity of breast cancer cell lines to neoadjuvant chemotherapeutic drugs. This may present a promising solution to overcome drug resistance.
over 3 years ago
IO biomarker
|
MTA2 (Metastasis Associated 1 Family Member 2) • RELA (RELA Proto-Oncogene)
Furthermore, circMAN1A2 knockdown inhibited xenograft tumour growth in vivo, and the overexpression of circMAN1A2 was associated with the progression of gastric cancer. Hence, Helicobacter pylori induced circMAN1A2 expression to promote the carcinogenesis of gastric cancer, and circMAN1A2 might be a new potential diagnostic marker and therapeutic target for gastric cancer.
Our results demonstrated that concomitantly used melatonin and sorafenib could significantly reduce the abilities of migration and invasion of RCC cells through inhibiting MTA2. We considered that this novel promising combination strategy towards the treatment of RCC, but further studies are warranted.
The newly identified TTC39A-AS1/miR-483-3p/MTA2 pathway was revealed to be a critical regulator in the tumorigenicity of BC, possibly offering a novel therapeutic direction for the anticancer treatment of BC.
over 4 years ago
Journal
|
MTA2 (Metastasis Associated 1 Family Member 2) • MIR483 (MicroRNA 483)